11 patients had a positive FDG PET study and a negative SRS study. Results: 49 patients had positive findings on both SRS and FDG PET/CT studies.12 patients showed a positive SRS study and negative FDG PET study. The findings were validated using available histological, imaging and follow up findings. The SPECT and PET results were interpreted independently by 2 nuclear medicine physicians and the corresponding studies were compared lesion by lesion for the final analysis. Materials and Methods: 72 patients (age - 18-72 years) with a known diagnosis of neuroendocrine tumor were prospectively studied.SRS using 99mTc- HYNIC TOC SPECT/CT and GLUT imaging with FDG PET/CT study were performed in all the patients. 2) To identify the subgroups and suitability for peptide therapy. Aim: 1) To study the variable expression of somatostatin and GLUT receptors in pathologically proven neuroendocrine tumors at primary and metastatic sites. Introduction: A combined imaging approach using FDG PET (GLUT expression) and SRS (somatostatin Receptor expression) is necessary in order to stratify patients of NET's, for appropriate treatment planning. Singh Abhijit, Zade A, Shah Sneha, Purandare CN, Rangarajan Vĭepartment of Radio Diagnosis, Bioimaging Unit, Tata memorial Hospital, Parel, Mumbai - 400 012, India Available from: Ĭombined imaging approach to Neuroendocrine tumors using somatostatin receptor scintigraphy with 99mTc-HYNIC TOC SPECT/CT and 18 F FDG PET/CT- Implications for targeted peptide therapy
0 Comments
Leave a Reply. |